» Articles » PMID: 21433042

Diclofenac Inhibits Tumor Necrosis Factor-α-induced Nuclear Factor-κB Activation Causing Synergistic Hepatocyte Apoptosis

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2011 Mar 25
PMID 21433042
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Drug-induced liver injury (DILI) is an important clinical problem. It involves crosstalk between drug toxicity and the immune system, but the exact mechanism at the cellular hepatocyte level is not well understood. Here we studied the mechanism of crosstalk in hepatocyte apoptosis caused by diclofenac and the proinflammatory cytokine tumor necrosis factor α (TNF-α). HepG2 cells were treated with diclofenac followed by TNF-α challenge and subsequent evaluation of necrosis and apoptosis. Diclofenac caused a mild apoptosis of HepG2 cells, which was strongly potentiated by TNF-α. A focused apoptosis machinery short interference RNA (siRNA) library screen identified that this TNF-α-mediated enhancement involved activation of caspase-3 through a caspase-8/Bid/APAF1 pathway. Diclofenac itself induced sustained activation of c-Jun N-terminal kinase (JNK) and inhibition of JNK decreased both diclofenac and diclofenac/TNF-α-induced apoptosis. Live cell imaging of GFPp65/RelA showed that diclofenac dampened the TNF-α-mediated nuclear factor kappaB (NF-κB) translocation oscillation in association with reduced NF-κB transcriptional activity. This was associated with inhibition by diclofenac of the TNF-α-induced phosphorylation of the inhibitor of NF-κB alpha (IκBα). Finally, inhibition of IκB kinase β (IKKβ) with BMS-345541 as well as stable lentiviral short hairpin RNA (shRNA)-based knockdown of p65/RelA sensitized hepatocytes towards diclofenac/TNF-α-induced cytotoxicity.

Conclusion: Together, our data suggest a model whereby diclofenac-mediated stress signaling suppresses TNF-α-induced survival signaling routes and sensitizes cells to apoptosis.

Citing Articles

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques.

Guo K, van den Beucken T Cell Biosci. 2024; 14(1):134.

PMID: 39488681 PMC: 11531151. DOI: 10.1186/s13578-024-01317-2.


In Vitro Hepatotoxicity of Routinely Used Opioids and Sedative Drugs.

Haller K, Doss S, Sauer M Curr Issues Mol Biol. 2024; 46(4):3022-3038.

PMID: 38666919 PMC: 11049542. DOI: 10.3390/cimb46040189.


Mapping Interindividual Variability of Toxicodynamics Using High-Throughput Transcriptomics and Primary Human Hepatocytes from Fifty Donors.

Niemeijer M, Wiecek W, Fu S, Huppelschoten S, Bouwman P, Baze A Environ Health Perspect. 2024; 132(3):37005.

PMID: 38498338 PMC: 10947137. DOI: 10.1289/EHP11891.


Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases.

Amanullah A, Upadhyay A, Dhiman R, Singh S, Kumar A, Ahirwar D Cancers (Basel). 2022; 14(18).

PMID: 36139546 PMC: 9496891. DOI: 10.3390/cancers14184385.


Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies.

Ballerini P, Contursi A, Bruno A, Mucci M, Tacconelli S, Patrignani P Front Pharmacol. 2022; 13:838079.

PMID: 35308229 PMC: 8927697. DOI: 10.3389/fphar.2022.838079.